Quanterix

Advances in biomarker technology are reshaping Alzheimer’s research and patient care 🧠 David H. Wilson, our VP of Clinical Strategy, recently spoke with SelectScience®’s Carrie Haslam on how Simoa® technology is enabling ultra-sensitive detection of key biomarkers, providing new ways to monitor disease progression and treatment response in Alzheimer’s and other neurodegenerative conditions. With the potential for non-invasive, cost-effective blood-based testing, this approach could make early detection and personalized care more accessible. Learn more about the science behind these breakthroughs and what it could mean for the future of Alzheimer’s research and treatment. https://bit.ly/48G3PlT #AlzheimersResearch #Biomarkers #NeurodegenerativeDisease #ClinicalResearch

Quanterix is thrilled to introduce a new era of cytokine biomarker analysis by combining the renowned Simoa® digital immunoassay technology and our innovative Advantage PLUS assay platform. Discover the ultra-sensitive, fully automated Simoa® Cytokine 4-Plex Advantage PLUS Assays - collectively analyze 11 key cytokine biomarkers, designed to deliver ultra-sensitivity with walk-away automation and robust reproducibility, providing deeper insights and scalable results like never before! Learn more: https://bit.ly/40vrLXb #Cytokines #Biomarkers #Diagnostics

Our team is in Houston and excited to attend the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, the world’s largest gathering for cancer immunotherapy. Join us November 6-10 to learn how Quanterix’s Simoa® Technology is advancing cancer research with unparalleled biomarker detection. Visit us at booth #817 – we can’t wait to connect! #SITC24 #Oncology #CancerResearch #Immunotherapy

In honor of Alzheimer's Awareness Month, we are excited to introduce Dr. Laia Montoliu Gaya, Assistant Professor at the University of Gothenburg, Sweden, as the speaker for Quanterix's upcoming webinar with SelectScience®! Dr. Montoliu-Gaya is the inventor of a unique mass spectrometry method for detecting tau species in blood, revolutionizing the early diagnosis of Alzheimer’s disease. She is also a co-inventor of a digital immunoassay for quantifying p-tau205 and has made significant strides in diagnosing Alzheimer's in individuals with Down syndrome. Join us to hear from Dr. Montoliu-Gaya as she discusses the recent advancements in Simoa® assays for diagnosing and staging Alzheimer's disease, while also expanding access to broader populations. Register for the webinar: https://bit.ly/48oalh6 #AlzheimersResearch #Diagnostics # #EarlyDetection #Neurodegeneration #DownSyndromeResearch #EndALZ #AlzheimersAwareness

Meet the speaker of our webinar tomorrow: Tore B. Stage, Professor of Translational Pharmacology and Head of Research at the Syddansk Universitet - University of Southern Denmark. Dr. Stage has over a decade of experience in translational research, including the first large-cohort study on neurofilament light chain (NfL) as a biomarker for paclitaxel-induced peripheral neuropathy. Join us in November for this exclusive webinar in partnership with Springer Nature, where Dr. Stage will explore the role of NfL in detecting neurotoxicity and its potential for identifying chemotherapy-induced peripheral neuropathy (CIPN). Register now: https://bit.ly/3NtUbca #Neurotoxicity #CIPN #Biomarkers #Webinar #TranslationalResearch #NfL

Mark your calendars! We’ll be discussing the utility of NFL as a biomarker for chemotherapy-induced peripheral neuropathy.

Quanterix had an incredible time at the 12th Annual Meeting of the International Cytokine & Interferon Society (ICIS) in Seoul, Korea! Our team enjoyed engaging in cutting-edge cytokine research and connecting with global experts.   Pictured below are our team members: Joyce C., Hajin Lee, Gilok Shin, and Jeong Seok MOON at the event. A big thank you to everyone who visited us at booth #59 to learn more about how our ultrasensitive biomarker detection technology is advancing the field.   #Cytokines2024 #CytokineInnovation #BiomarkerTechnology #GlobalScience

This past weekend, we proudly joined the Alzheimer's Association® Walk to End Alzheimer’s—the world’s largest fundraiser supporting Alzheimer’s care, research, and awareness. Held annually in over 600 communities, this inspiring event unites people of all ages and abilities in the fight against Alzheimer’s. As a sponsor, we were honored to host a table at the starting line and provide water along the route. Our team walked together, driven by the shared goal of advancing Alzheimer’s research and supporting the millions affected by this disease. Thank you to everyone who walked, donated, and supported this mission. Every step brings us closer to a world without Alzheimer’s. #EndAlz #WalktoEndAlzheimers #AlzheimersAwareness

Great start to the morning here at #CTAD24 in Madrid, Spain! 🌞🇪🇸 We kicked off interviews today with Michael Miller, chief operating officer at Quanterix, who had a conversation with us about 2 poster presentations focused on enhancing the characterization of #Alzheimers disease-related neurodegeneration in blood and reducing the intermediate range of a high accuracy plasma p-tau 217 test for amyloid detection. Stay tuned for the video interview! CTAD Clinical Trials on Alzheimer's Disease

Our team is having an incredible time at CTAD 2024! Here’s where you can find Quanterix this year: 1️⃣ Fireside Chat: Join us for an exclusive discussion with Dr. Henrik Zetterberg on the latest in Alzheimer’s research on October 30 at 6:30 pm CET at the Madrid Marriott Lounge Bar. 2️⃣ Networking Reception: Connect with peers and our team right after the Fireside Chat. 3️⃣ Poster Sessions: Find us at Session 2, showcasing research on p-Tau 217 & BD-Tau. 4️⃣ One-on-One Sessions: Schedule a personal meeting with our team. We’d love to connect! https://lnkd.in/gkyRBgYC #CTAD2024 #AlzheimersResearch #Networking #Diagnostics Zachary Fernandes, Kirk Stockwood, Adam Shepro, Milena Dumont Milutinovic, Michael Miller